Karyopharm Therapeutics Inc
KPTI6.260USD
+0.170+2.79%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
54.47MCap. mercado
PérdidaP/E TTM
Más Datos de Karyopharm Therapeutics Inc Compañía
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Información de Karyopharm Therapeutics Inc
Símbolo de cotizaciónKPTI
Nombre de la empresaKaryopharm Therapeutics Inc
Fecha de salida a bolsaNov 06, 2013
Director ejecutivoPaulson (Richard A)
Número de empleados279
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 06
Dirección85 Wells Avenue
CiudadNEWTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02459
Teléfono16176580600
Sitio Webhttps://karyopharm.com/
Símbolo de cotizaciónKPTI
Fecha de salida a bolsaNov 06, 2013
Director ejecutivoPaulson (Richard A)
Ejecutivos de Karyopharm Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
88.34K
+32415.00%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
80.71K
+32415.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
39.66K
+32415.00%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
88.34K
+32415.00%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
80.71K
+32415.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
39.66K
+32415.00%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
12.58%
Opaleye Management Inc.
5.19%
J. Wood Capital Advisors LLC
4.29%
The Vanguard Group, Inc.
3.06%
Adage Capital Management, L.P.
2.30%
Otro
72.58%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
12.58%
Opaleye Management Inc.
5.19%
J. Wood Capital Advisors LLC
4.29%
The Vanguard Group, Inc.
3.06%
Adage Capital Management, L.P.
2.30%
Otro
72.58%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
18.69%
Hedge Fund
9.85%
Corporation
4.29%
Individual Investor
2.18%
Investment Advisor/Hedge Fund
2.09%
Venture Capital
0.86%
Research Firm
0.66%
Otro
61.38%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
232
6.66M
36.38%
+1.16M
2025Q3
251
4.11M
24.14%
-1.36M
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
2.30M
13.51%
+1.60M
+228.71%
Oct 31, 2025
Opaleye Management Inc.
949.91K
5.57%
+949.91K
--
Oct 10, 2025
J. Wood Capital Advisors LLC
784.80K
4.6%
+326.67K
+71.30%
Oct 14, 2025
The Vanguard Group, Inc.
408.22K
2.39%
-110.05K
-21.23%
Sep 30, 2025
Adage Capital Management, L.P.
421.32K
2.47%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
183.86K
1.08%
-991.00
-0.54%
Sep 30, 2025
Catalio Capital Management, LP
142.98K
0.84%
-3.03K
-2.07%
Sep 30, 2025
Avidity Partners Management LP
134.57K
0.79%
--
--
Sep 30, 2025
Marshall Wace LLP
128.45K
0.75%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.01%
Global X Russell 2000 Covered Call ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Fidelity Enhanced Small Cap ETF
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
